Novo Nordisk (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported Friday.

The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said.

In one 10,000 patient study, those with early-stage cancers who started GLP-1 drugs after diagnosis were less likely to see their cancer spread, the report said.

Novo Nordisk and Eli Lilly did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)